logo

Kadmon Holdings Llc (KDMN)



Trade KDMN now with
  Date
  Headline
10/6/2017 8:11:53 AM FDA Grants Orphan Drug Designation To Kadmon’s KD025 For Treatment Of CGVHD
9/26/2017 9:10:00 AM Kadmon Reports Pricing Of Public Offerings Of An Aggregate Of 24 Mln Common Shares
9/25/2017 4:18:49 PM Kadmon Announces Proposed Public Offering Of Common Stock And Warrants
8/7/2017 9:07:43 AM Kadmon: FDA Grants Orphan Drug Designation To Tesevatinib For Treatment Of EGFR-Mutated Non-Small Cell Lung Cancer
7/11/2017 8:03:11 AM Kadmon Announces Interim Phase 2 Data Of KD025 In Chronic Graft-Versus-Host Disease
3/8/2017 9:07:00 AM Kadmon Reports Approximately $23 Mln Equity Financing
11/9/2016 8:36:53 AM Kadmon Q3 Revenue $5.7 Mln Vs. $11.3 Mln Prior Year
8/29/2016 9:04:15 AM Kadmon Holdings Begins Phase 2 Clinical Trial Evaluating Tesevatinib In Glioblastoma
  
 
>